Fibrocell Science, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-11-18: Form 8-K; Period of report 2013-11-15; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-11-14: Form 8-K; Period of report 2013-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-10-01: Form 8-K; Period of report 2013-10-01; Description 8.01 Other Events; Details 8.01.
- 2013-09-26: Form 8-K; Period of report 2013-09-26; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-11-18 | 8-K | 2013-11-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 15, 2013, Fibrocell Science, Inc. (the “Company”) entered into an employment agreement with Mr. David Pernock, which replaces the Company’s prior agreement with Mr. Pernock, pursuant to which Mr. Pernock will continue to serve as the Company’s Chief Executive Officer for an initial term ending December 31, 2016, which may be renewed for an additional one-year term by mutual agreement. | d631681d8k.htm |
| 2013-11-14 | 8-K | 2013-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2013, Fibrocell Science, Inc. (the “Company”) issued a press release announcing the financial results for its third quarter ended September 30, 2013. | d628161d8k.htm |
| 2013-10-01 | 8-K | 2013-10-01 | 8.01 Other Events | 8.01 On October 1, 2013, Fibrocell Science, Inc. (the “Company”) issued a press release announcing the completion of its previously announced underwritten public offering of 11,000,000 shares of Company common stock at a public offering price of $4.10 per share. | d605770d8k.htm |
| 2013-09-26 | 8-K | 2013-09-26 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 26, 2013, the Company issued a press release announcing the entry into the underwriting agreement described in Item 1.01 of this Current Report on Form 8-K. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | d602777d8k.htm |
| 2013-09-26 | 8-K | 2013-09-25 | 8.01 Other Events | 8.01 On September 25, 2013, Fibrocell Science, Inc. (the “Company”) issued a press release announcing the Company’s intention to offer, subject to market and other conditions, shares of Company common stock in an underwritten public offering pursuant to its existing shelf registration statement. | d602769d8k.htm |
| 2013-09-10 | 8-K | 2013-09-10 | 7.01 Regulation FD Disclosure | 7.01 On September 10, 2013, Fibrocell Science, Inc. (the “Company”) posted the presentation attached as exhibit 99.1 on its web site. | d595870d8k.htm |
| 2013-08-26 | 8-K | 2013-08-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 26, 2013, Fibrocell Science, Inc. (the “Company”) entered into an employment agreement with Mr. Gregory Weaver pursuant to which Mr. Weaver agreed to serve as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of the Company commencing September 3, 2013 for an initial term ending August 26, 2015, which may be renewed for an additional one-year term by mutual agreement. | d589604d8k.htm |
| 2013-08-05 | 8-K | 2013-08-05 | 7.01 Regulation FD Disclosure | 7.01 On August 5, 2013, Fibrocell Science, Inc. (the “Company”) posted the presentation attached as exhibit 99.1 on its web site. | d578216d8k.htm |
| 2013-07-22 | 8-K | 2013-07-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On July 19, 2013, the board of directors of Fibrocell Science, Inc. (the “Company”) approved a revised compensation program for its non-employee board members pursuant to which, effective August 1, 2013, (i) each non-employee member of the board of directors will receive annualized compensation of $45,000; (ii) the lead independent director will receive annualized compensation of $15,000; (iii) the chair of the audit committee of the board of directors will receive annualized compensation of $14,000 and all other members of the committee will receive annualized compensation of $7,000; (iv) the chair of the compensation committee of the board of directors will receive annualized compensation of $10,000 and all other members of the committee will receive annualized compensation of $5,000; and (v) the chair of the nominating and corporate governance committee of the board of directors will receive annualized compensation of $7,000 and all other members of the committee will receive annualized compensation of $3,000. 5.03 The information set forth in Item 5.07 below is incorporated herein by reference. 5.07 On July 19, 2013, the Company held its 2013 Annual Meeting of Stockholders at the Company’s offices in Exton, Pennsylvania. | d571995d8k.htm |
| 2013-07-01 | 8-K | 2013-06-28 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained in Item 1.01 is hereby incorporated by reference. | d562334d8k.htm |
| 2013-06-28 | 8-K | 2013-06-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 28, 2013, Fibrocell Science, Inc. (the “Company”) and Declan Daly, the Company’s Chief Financial Officer, entered into an employment transition letter pursuant to which Mr. Daly has agreed to remain as the Company’s Chief Financial Officer until the Company names a successor Chief Financial Officer or until September 30, 2013, whichever occurs sooner. | d561519d8k.htm |
| 2013-05-07 | 8-K | 2013-05-07 | 7.01 Regulation FD Disclosure | 7.01 On May 7, 2013, Fibrocell Science, Inc. (the “Company”) posted the presentation attached as exhibit 99.1 on its web site. | d533468d8k.htm |
| 2013-04-29 | 8-K | 2013-04-26 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On April 26, 2013, Fibrocell Science, Inc. (the “Company”) filed a Certificate of Amendment (“Certificate of Amendment”) to its Restated Certificate of Incorporation (the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware, to effect a 1-for-25 reverse stock split of the Company’s common stock (the “Reverse Stock Split”). | d528681d8k.htm |
| 2013-03-14 | 8-K | 2013-03-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The information set forth in Item 8.01 is incorporated by reference herein. | d502307d8k.htm |
| 2013-03-05 | 8-K | 2013-03-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 4, 2013, the board of directors of Fibrocell Science, Inc. (the “Company”) approved the appointment of Douglas J. Swirsky to the Company’s board of directors. | d496270d8k.htm |
| 2013-02-21 | 8-K | 2013-02-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective February 21, 2013, the board of directors of Fibrocell Science, Inc. (the “Company”) approved the appointment of Christine St.Clare to the Company’s board of directors. | d491978d8k.htm |
| 2013-01-09 | 8-K | 2013-01-09 | 7.01 Regulation FD Disclosure | 7.01 On January 9, 2013, Fibrocell Science, Inc. (the “Company”) posted the a presentation attached as exhibit 99.1 on its web site. | d462689d8k.htm |